Diabetes

Automated insulin delivery for people with type 2 diabetes is entering a new phase. What once seemed reserved for highly specialized endocrinology clinics is now moving steadily into primary care offices across the country. Following the updated 2026 American Diabetes Association Standards of Care and recent FDA clearances, more adults …

A glucose alarm goes off during dinner. Another alert appears at 2 a.m. A smartphone app flashes warnings about rising blood sugar before the day even starts. Diabetes technology promises better control, yet for some patients, the nonstop stream of notifications and health data can feel mentally exhausting. Clinicians are …

Screening for fatty liver disease in patients with diabetes is no longer limited to identifying elevated liver enzymes or calculating a fibrosis score during an annual visit. Instead, clinicians are entering an era where diabetes care and hepatology increasingly overlap, especially as metabolic dysfunction-associated steatotic liver disease, or MASLD, becomes …

Prediabetes has traditionally been diagnosed during annual physical exams through fasting glucose tests or A1C measurements. However, new diabetes prevention tools and wearable technologies are rapidly changing that model. Today, wearable devices, continuous glucose monitors (CGMs), and predictive metabolic tracking tools are giving people real-time insight into their glucose patterns …

Young adults diagnosed with type 2 diabetes early in life often face a more aggressive disease course than older adults. While metformin has long served as the standard first-line therapy, many clinicians are now reconsidering whether a “metformin-first and wait” strategy is enough for this higher-risk population. As research continues …

Diabetic retinopathy remains one of the leading causes of preventable blindness worldwide. Yet despite clear screening guidelines, many patients with diabetes still miss their annual retinal exams. Busy schedules, limited specialist access, transportation barriers, and lack of awareness often delay diagnosis until vision changes become permanent. As healthcare systems search …

Cancer treatment is evolving rapidly, and with that progress comes a new challenge for clinicians managing glucose disorders. As immune checkpoint inhibitors (ICIs) and PI3K inhibitors become more widely used in oncology, therapy-related hyperglycemia is appearing more often in clinical practice. Many patients receiving cancer treatment now face unexpected glucose …

New advances in diabetes technology are moving beyond glucose alone. While continuous glucose monitoring transformed diabetes management over the last decade, wearable ketone monitoring systems are now emerging as the next major innovation. Researchers, device manufacturers, and international diabetes organizations are increasingly focused on whether real-time ketone data can help …

A patient arrives at the pharmacy expecting their usual insulin refill, only to discover the box, brand name, and pen device suddenly look different. The pharmacist explains that the medication is an interchangeable biosimilar approved for automatic substitution. Although the insulin is considered clinically equivalent, the unexpected switch can still …

Managing Type 2 diabetes used to follow a relatively predictable path. Clinicians often started with metformin and added medications gradually as glucose control worsened. Today, however, diabetes care looks very different. The number of available therapies has expanded rapidly, and while that growth has improved patient outcomes, it has also …